Skip to main content

Practice Tips

  • Quintiles, IMS Health complete merger

    DANBURY, Conn. and RESEARCH TRIANGLE PARK, N.C. — Quintiles IMS on Monday announced that the merger between Quintiles Transnational Holdings and IMS Health has been completed. 
     
    Shares of IMS Health were halted from trading Monday on the New York Stock Exchange and will no longer be traded. At the time of the effective merger, each IMS Health share was converted into 0.3840 shares of Quintiles stock. The combined company will be known as Quintiles IMS Holdings. 
     

  • BioPlus Specialty Pharmacy gets ACHC oncology accreditation

    ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy announced Tuesday that it had received accreditation from the Accreditation Commission for Health Care (ACHC) with a distinction in oncology. 
     
    The distinction recognizes BioPlus’s abilities to deliver medications for cancer-specific conditions, identifying the toxic nature of the medications and collaborating with the physician and patient for best outcomes while containing costs. 
     

  • FDA approves Janssen’s Stelara to treat Crohn’s disease

    SILVER SPRING, Md. — Janssen Biotech announced Monday that the Food and Drug Administration had approved its Stelara (ustekinumab) to treat moderately to severely active Crohn’s disease.  
     
    It is now indicated for adults with Crohn’s disease who have failed or were intolerant to corticosteroid or immunomodulator treatments, but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant of one or more TNF blocker treatment. 
     

  • FDA approves low-dose appetite suppressant Lomaira

    SILVER SPRING, Md. — The Food and Drug Administration has approved KVK Tech’s Lomaira (phentermine HCl), the company announced Tuesday. The drug is indicated for short-term use to aid in weight reduction in obese and overweight patients (patients with body mass indices of 30 or higher and 27 or higher, respectively) with at least one weight-related condition, including high blood pressure and diabetes. 
     

  • DSN, Becton Dickinson team up to help educate community pharmacies about injectable diabetes treatments

    NEW YORK, N.Y. — In response to the ever-changing healthcare system needs and the needs of the growing number of people living with diabetes, Drug Store News has created educational resources for community pharmacists and technicians targeting injectable diabetes medications.

  • Health Mart tops J.D. Power pharmacy study in customer satisfaction

    SAN FRANCISCO — In a recent J.D. Power survey, Health Mart, the network of more than 4,700 locally owned community pharmacies, took top marks in customer satisfaction among chain drug pharmacies. The J.D. Power Pharmacy Satisfaction Study based its results on more than 15,000 pharmacy customers’ responses. 
     

  • FDA advisory committees recommend removing Chantix boxed warning

    SILVER SPRING,  Md. — The Food and Drug Administration’s advisory committees on psychopharmacologic drugs and drug safety risk management held a recommended Wednesday that the boxed warning accompanying Pfizer’s smoking cessation drug Chantix be removed. 
     

  • Pfizer launches Moodivator app for patients with depression

    NEW YORK — Pfizer has launched a new app, Moodivator, aimed at helping to motivate and encourage patients with depression. The app is designed to help patients track their mood, set goals and establish routines as a complement to their treatment for depression, which can include talk therapy, medication and other approaches. 
     
X
This ad will auto-close in 10 seconds